Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech — Update
By Katherine Hamilton
Arbutus Biopharma and its licensee Genevant filed three patent infringement lawsuits against Pfizer and BioNTech for its lipid nanoparticle technology.
The clinical-stage biopharmaceutical company is seeking monetary relief and injunctions against Pfizer and BioNTech's Covid-19 vaccines using lipid nanoparticle technology, Arbutus said Thursday.
Arbutus filed the lawsuits in Canada and the United Patent Court, which covers several European countries.
The actions expand on Arbutus' continuing proceedings in a New Jersey district court, where the company is seeking compensation for alleged infringement of five U.S. patents in Pfizer and BioNTech's Covid-19 vaccines.
BioNTech said it was aware of the lawsuits and wouldn't comment on its legal strategy. Pfizer didn't immediately respond to a request for comment.
Separately, Arbutus said it received $178 million from Moderna earlier this month, representing a settlement agreement to resolve patent infringement litigation related to Moderna's Covid-19 vaccines.
Arbutus said it expects to return capital to shareholders starting in the third quarter through repurchases of up to $230 million of its common shares.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 16, 2026 09:07 ET (13:07 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States